{"filing":{"accession_number":"0001193125-26-357817","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"nbp_-_6-k_for_corporate_.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000119312526357817/nbp_-_6-k_for_corporate_.htm"},"events":[{"id":28683,"run_id":26246,"accession_number":"0001193125-26-357817","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This is a corporate presentation slide deck furnished as an exhibit to a 6-K, disclosing NovaBridge's business strategy, pipeline, clinical development progress, and organizational structure. The presentation highlights clinical milestones (givastomig Phase 1b data, Phase 3 readiness, VIS-101 Phase 2b initiation), asset sourcing strategy, and multiple value-creation pathways across established and emerging franchises. While it contains forward-looking statements and strategic positioning rather than discrete transactional events, the disclosure of material clinical data (77% ORR, $5B+ peak sales potential), regulatory progress (Fast Track Designation, Accelerated Approval Eligibility), and partnership discussions affecting multiple programs constitutes material operational and strategic disclosure affecting investor assessment of the company's pipeline and execution capability.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-08-20","form":"6-K","submitted_at":null,"items":[{"id":30708,"accession_number":"0001193125-26-357817","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a corporate presentation slide deck furnished as an exhibit to a 6-K, disclosing NovaBridge's business strategy, pipeline, clinical development progress, and organizational structure. The presentation highlights clinical milestones (givastomig Phase 1b data, Phase 3 readiness, VIS-101 Phase 2b initiation), asset sourcing strategy, and multiple value-creation pathways across established and emerging franchises. While it contains forward-looking statements and strategic positioning rather than discrete transactional events, the disclosure of material clinical data (77% ORR, $5B+ peak sales potential), regulatory progress (Fast Track Designation, Accelerated Approval Eligibility), and partnership discussions affecting multiple programs constitutes material operational and strategic disclosure affecting investor assessment of the company's pipeline and execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:02:46.299612+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30708,"accession_number":"0001193125-26-357817","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a corporate presentation slide deck furnished as an exhibit to a 6-K, disclosing NovaBridge's business strategy, pipeline, clinical development progress, and organizational structure. The presentation highlights clinical milestones (givastomig Phase 1b data, Phase 3 readiness, VIS-101 Phase 2b initiation), asset sourcing strategy, and multiple value-creation pathways across established and emerging franchises. While it contains forward-looking statements and strategic positioning rather than discrete transactional events, the disclosure of material clinical data (77% ORR, $5B+ peak sales potential), regulatory progress (Fast Track Designation, Accelerated Approval Eligibility), and partnership discussions affecting multiple programs constitutes material operational and strategic disclosure affecting investor assessment of the company's pipeline and execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:02:46.299612+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-08-20"}]}